Strider Canada: A Randomized Controlled Trial Of Sildenafil Therapy In Dismal Prognosis Early-Onset Intrauterine Growth Restriction
Bibliographic record
Abstract
Early-onset placental intrauterine growth restriction (EO IUGR) is associated with a high risk of perinatal morbidity and mortality. In association with reduced circulating placental growth factor (PLGF) EO IUGR results from abnormal placentation with inadequate remodelling of the maternal uteroplacental arteries. There is no known treatment for placental IUGR. Management involves intensive fetal surveillance with delivery with evidence of serious fetal compromise. However, remote from term, delivery is associated with significant perinatal mortality and morbidity. Sildenafil vasodilates the uteroplacental vessels of IUGR-affected pregnancies and may represent a novel therapy. Sildenafil has been used in pregnant women with pulmonary artery hypertension without adverse events, and has a good fetal safety profile from animal studies and a randomised controlled trial (RCT) of 17 women who received sildenafil (18 placebo-treated; non-significant increase in median birth weight of 367g after median 4.5d). We used sildenafil in a cohort of 12 women with severe EO IUGR as compassionate therapy. Compared with 17 sildenafil-naïve EO IUGR pregnancies, sildenafil appeared to improve daily fetal growth velocity (92% vs 41%, Fisher’s p=0.008; OR 16 [95% CI 2, 151]) and were more frequently live born (75% vs 35%, p=0.042, OR 6 [1.1, 28])). Therefore, there are sufficient data to support an RCT. We will target the fetus as patient. STRIDER Canada is one of a consortium of STRIDER randomised controlled trials (RCTs) each of which is designed to determine whether or not maternal treatment with sildenafil citrate improves markers of perinatal wellbeing. The overarching aim of the STRIDER Canada trial is to determine whether maternal treatment with oral sildenafil citrate improves perinatal outcomes in pregnancies complicated by early-onset IUGR without increasing risks to the mother.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.001 | 0.002 |
| Meta-epidemiology (narrow) | 0.001 | 0.000 |
| Meta-epidemiology (broad) | 0.003 | 0.001 |
| Bibliometrics | 0.000 | 0.001 |
| Science and technology studies | 0.000 | 0.001 |
| Scholarly communication | 0.001 | 0.001 |
| Open science | 0.001 | 0.000 |
| Research integrity | 0.001 | 0.002 |
| Insufficient payload (model declined to judge) | 0.011 | 0.001 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".